Trial Profile

A phase 1b proof of concept trial of SZN-1326 for Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SZN-1326 (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; Proof of concept
Sponsors Surrozen

Most Recent Events

18 Jan 2024 According to Surrozen media release, company will discontinue clinical development of SZN-1326 in inflammatory bowel disease due to the challenges of identifying a safe and effective dose for further development and other strategic considerations.
18 Jan 2024 Status changed to discontinued, according to a Surrozen media release.
16 May 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com